Proteus Digital Health today said the FDA expanded the indications for use for its sensor-enabled pill technology, claiming it as the only FDA-approved device designed to measure medication adherence. “We are delighted that our collaborative work with the FDA continues to enable positive progress,” co-founder & chief medical officer Dr. George Savage said in prepared remarks. […]
California-based Proteus Digital Health closed a Series G funding round this week with more than $172 million pledged in support of the company’s ingestible sensor-laden pills.
Bob Langer, MIT professor and bioengineering hot-shot, was chosen to recieve the 2011 Alpert Prize for his advancements in drug delivery and tissue engineering.
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Chris Brinsmead has joined the company as Chairman, Proteus Biomedical Europe. Brinsmead has over 30 years of experience in the global pharmaceutical industry and more recently advising the United Kingdom government on health and life sciences policy. He will be instrumental in guiding the commercial launch of Proteus’s first product, Helius™, and the development of Proteus’s organization in Europe.
European Union doctors may now begin prescribing Proteus Biomedical Inc.’s “Raisins.”
The Redwood City, Calif.-based company won CE Mark approval for its ingestible “Raisin” sensor and personal physiologic monitor system.